COST-UTILITY ANALYSIS OF LORLATINIB FOR FIRST-LINE TREATMENT FOR ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA

被引：0
|
作者：
He, X. [1 ]
Fu, S. [1 ]
机构：
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE69
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [21] Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
    Gourzoulidis, George
    Zisimopoulou, Oresteia
    Liavas, Andrianos
    Tzanetakos, Charalampos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (03) : 375 - 385
  • [22] BUDGET IMPACT ANALYSIS OF BRIGATINIB FOR FIRST-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ITALY
    Urbinati, D.
    La Malfa, P.
    Demma, F.
    Viti, R.
    Cranmer, H.
    Hernandez, L. G.
    VALUE IN HEALTH, 2022, 25 (01) : S87 - S87
  • [23] A cost minimization analysis of first-line polychemotherapy regimens in the treatment of advanced non-small cell lung cancer
    Le Lay, K
    Riou-França, L
    Avoinet, S
    Chemali, N
    Vergnenègre, A
    Launois, R
    VALUE IN HEALTH, 2004, 7 (06) : 676 - 676
  • [24] A cost minimization analysis of first-line polychemotherapy regimens in the treatment of advanced non-small cell lung cancer
    Le Lay, K
    Avoinet, S
    Chemali, N
    Vergnenegre, A
    Launois, R
    LUNG CANCER, 2005, 49 : S255 - S255
  • [25] COST-UTILITY ANA LYSIS OF ERLOTIB VERSUS STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    Nguyen, T.
    VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
  • [26] A randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer
    Shaw, A. T.
    Bauer, T. M.
    Takahashi, T.
    Baik, C. S.
    Polli, A.
    Carpentieri, M.
    Martini, J-F.
    Solomon, B. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
    Wang, Hao
    Zeng, Chenxin
    Li, Xin
    Wang, Youjie
    Li, Xinyi
    Ge, Weihong
    FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
  • [28] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [29] Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
    Wang, Wan-Qing
    Xu, Tao
    Zhang, Jing-Jing
    Wang, Yong
    Wang, Yao
    Zhang, Wei
    Zhu, Jian-Guo
    JOURNAL OF THORACIC DISEASE, 2023, 15 (04) : 1935 - 1947
12345